Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4749922 | 0.91 | KDM4E (0.45) | KDM4EGAANPC1RAB9APOLB | |
| SCHEMBL14020621 | 0.91 | KDM4E (0.34) | KDM4ENPC1RAB9AMAPTLMNA | |
| SCHEMBL3441528 | 0.80 | POLB (0.47) | KDM4EGAANPC1RAB9APOLB | |
| SCHEMBL4885880 | 0.78 | CNR1 (0.39) | KDM4ENPC1RAB9AMAPTMAPK1 | |
| SCHEMBL4894672 | 0.75 | MAPK14 (0.34) | KDM4ENPC1RAB9APOLBMAPT | |
| SCHEMBL4786438 | 0.75 | CNR1 (0.43) | NPC1RAB9AMAPTLMNA | |
| SCHEMBL4897158 | 0.71 | MAPT (0.41) | KDM4EMAPTLMNANPSR1 | |
| SCHEMBL4891117 | 0.69 | ENPP2 (0.40) | KDM4EMAPTABCB1 | |
| SCHEMBL4897672 | 0.69 | FFAR2 (0.40) | GAAMAPTLMNANPSR1 | |
| SCHEMBL4892358 | 0.68 | MAPK1 (0.45) | KDM4EGAANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | claimed |
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | GABRB2, GABRA2, GABBR2 | KDM4E 2374/4885GAA 731/4885NPC1 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.